It is also shown that Jak/STAT3 activation was frequently present in EGFR inhibitor resistance HNSCC cases, and addition of STAT3 inhibitor to EGFR blocking strategies significantly enhanced antitumour effects in vivo [149]. Here, STAT3 is linked to head and neck squamous cell carcinoma.